Neoepitopes are short peptide sequences that mutate in tumors and can generate an immune response. A description of the approach was published in the June issue of the Journal for Immunotherapy of Cancer.

The approach combines the two firms' bioinformatics expertise in order to predict neoepitopes based on genomic and expression analyses that will likely prompt an immune response, and is used with ImmunityBio's Adeno platform, they said.

The method can help identify tumor-specific immunogenic targets for individualized treatment including chimeric antigen receptor T-cell therapies and vaccines. Efficacy of these therapies could be further enhanced by combining them with an immune enhancer such as ImmunityBio's Anktiva or natural killer cells.

The technology was developed in collaboration with researchers at the Friedrich Alexander University in Erlangen, Germany, and the U.S. National Cancer Institute in Bethesda, MD.

Early data suggest ImmunityBio's COVID-19 vaccine is effective
ImmunityBio has reported initial data from a phase I trial suggesting its COVID-19 vaccine candidate stimulates the generation of T cells reactive to...

ImmunityBio, NantKwest to begin mixed COVID-19 vaccine trial
The U.S. Food and Drug Administration (FDA) has authorized ImmunityBio and NantKwest to expand phase I testing of a bivalent human adenovirus 5 T-cell...

ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated...

ImmunityBio uses Microsoft software to visualize SARS-CoV-2 spike protein
ImmunityBio has released results from a molecular dynamics simulation, conducted in collaboration with Microsoft, that provided a visualization of the...

ImmunityBio, NantKWest to merge
ImmunityBio and NantKWest have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a new immunotherapy and...